Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05981235
Other study ID # D9540C00001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 14, 2023
Est. completion date November 1, 2028

Study information

Verified date July 2023
Source Peking University
Contact Lin Shen, PHD
Phone 01088196090
Email linshenpku@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.


Description:

Qualified researchers can request access to anonymized individual patient-level data from sponsor or the collaborator group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the sponsor disclosure commitment. Yes, indicates that sponsors are accepting requests for IPD, but this does not mean all requests will be shared.


Recruitment information / eligibility

Status Recruiting
Enrollment 96
Est. completion date November 1, 2028
Est. primary completion date June 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1Capable of giving signed informed consent and keep compliance with the requirements and restrictions listed in the ICF and in this protocol. 2Age = 18 years at the time of signing the informed consent. 3At least 1 lesion, that qualifies as a RECIST v1.1 target lesion at baseline. Histologically confirmed diagnosis of unresectable or metastatic GI adenocarcinoma that has failed prior lines systemic treatment or with standard anticancer therapy. 4Confirmation of CLDN18.2 expression determined by IHC . 5ECOG PS of 0 to 1. 6 Life expectancy of > 12 weeks. 7Evidence of appropriate organ function, as determined by clinical laboratory values. 8Participants of childbearing potential (including woman of childbearing potential and males who have a partner) must take highly effective contraception measure. Exclusion Criteria: - 1.Prior treatment with any CAR-T cell therapy. 2.History of upper digestive tract bleeding secondary to previous CLDN18.2-targeting therapies; clinically significant unstable or active peptic ulcer disease or upper digestive tract bleeding 3.Cancer-related spinal cord compression, leptomeningeal disease, or brain metastases. 4.Receipt of the last dose of anticancer therapy within 5 half-lives or = 21 days prior to apheresis, treatment radiotherapy within 6 weeks (loco-regional palliative radiotherapy within 7 days) prior to apheresis. 5.Treatment with any anticoagulant or antiplatelet therapy. 6.History of, or active, bleeding diatheses. 7.Active or chronic infection disease (s). 8.History of another primary malignancy = 3 years before enrolment. 9.Any history of autoimmune neurological conditions. 10.Other active autoimmune or inflammatory disorders. 11.Stroke, intracranial haemorrhage, or seizure within 6 months of apheresis. 12.Active uncontrolled epilepsy. 13.Cardiac disease, including arrhythmias, QT prolongation, cardiomyopathy and unstable ischaemic heart disease. 14.Uncontrolled intercurrent illness. 15.Steroids or other immunomodulators of systemic therapeutic dose within 14 days prior to apheresis. 16.Prior pegylated G-CSF within 60 days before apheresis. Prior G-CSF/granulocyte-macrophage colony stimulating factor (GM-CSF) within 14 days before apheresis. 17.Any prohibited medication. 18.Major surgery within 2 weeks prior to apheresis, or planned surgery within 4 weeks after study intervention. 19.Any history of life-threatening allergies, hypersensitivity, or severe infusion reaction to monoclonal antibodies or biological therapies, or intolerance to the CAR-T product or its excipients. 20.Toxicity from previous anticancer therapy that has not resolved to baseline levels or to = Grade 1 prior to apheresis. 21.Female participants who are pregnant or breastfeeding or expect to be pregnant or breastfeeding during the study. 22.Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 23.Receipt of live or live attenuated vaccine within 30 days prior to the start of lymphodepletion. 24.Participant has any medical or psychiatric condition.

Study Design


Intervention

Biological:
AZD6422 CLDN18.2 CAR-T product
AZD6422 CAR-T product infusion after pre-conditioning

Locations

Country Name City State
China Beijing Cancer Hospital Beijing

Sponsors (2)

Lead Sponsor Collaborator
Peking University AstraZeneca

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent AEs, AESIs, and SAEs. Incidence of treatment-emergent AEs, AESIs, and SAEs. Within 24 months of the last AZD6422 infusion or the start of a new anticancer treatment
Primary Occurrence of Dose limiting toxicity. Occurrence of DLTs (Dose limiting toxicity). Within 28 days after the first infusion
Primary Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG. Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG. Within 28 days after the first infusion
Secondary ORR The proportion of participants who have a confirmed CR or confirmed PR as determined by the investigator at local site per RECIST v1.1. 24 months post AZD6422 infusion
Secondary DoR The time from first documented confirmed response until date of documented progression of disease per RECIST v1.1 as determined by investigator at local site or death due to any cause. 24 months post AZD6422 infusion
Secondary DCR The proportion of participants who have a confirmed CR, confirmed PR, or who have SD per RECIST v1.1 as assessed by the investigator at local site and derived from the raw tumor data for at least 11 weeks after infusion date. 24 months post AZD6422 infusion
Secondary PFS Time from infusion date until progression per RECIST v1.1 as assessed by the investigator at local site, or death due to any cause. 24 months post AZD6422 infusion
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05922358 - Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors Phase 2
Recruiting NCT06152757 - BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors Early Phase 1
Terminated NCT04171141 - Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. Phase 1
Completed NCT01552291 - The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies Phase 4
Active, not recruiting NCT03833700 - A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) Phase 1
Recruiting NCT06085365 - Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors Phase 3
Completed NCT01640665 - Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Phase 1
Recruiting NCT04629326 - PD-L1 Targeting Molecular Imaging of Solid Tumors N/A
Recruiting NCT05262335 - Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) Phase 2
Terminated NCT01648465 - Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Phase 2
Not yet recruiting NCT06263205 - Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques N/A